Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (69)

IV-01Nicolas Frances

A translational threshold model to assess exposure-driven QTc changes

Thursday 15:00-16:30

IV-02Ben Francis

Using Stochastic Control Methods and Pharmacokinetics to Individualise Drug Therapy: A Case Study with the Enzyme Inhibitor Imatinib.

Thursday 15:00-16:30

IV-03

Practical Implications of Ontology and Global Standards for Model-based Data Analysis

Thursday 15:00-16:30

IV-04Nicolas Frey

Short- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis

Thursday 15:00-16:30

IV-05Lena Friberg

Myelosuppression as a Biomarker of Tumor Response in Docetaxel Treated Metastatic Breast Cancer Patients

Thursday 15:00-16:30

IV-06Anne-Kristina Mercier

A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A

Thursday 15:00-16:30

IV-07

Relevance of Endogenous IgG Binding to FcRn in PBPK Models of Therapeutic mAbs

Thursday 15:00-16:30

IV-08Aline Fuchs

Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools

Thursday 15:00-16:30

IV-09Samira Garonzik

Development of PK/PD Models to describe Pharmacokinetics and Biomarker Responses for Dovitinib (TKI258)

Thursday 15:00-16:30

IV-10Peter Gennemark

Experimental design based on mechanistic mathematical modeling of body composition and energy turnover

Thursday 15:00-16:30

IV-11Cecile Gerard

Determination of the most influential sources of variability of tacrolimus trough blood levels in adult liver transplant patients: a bottom-up approach

Thursday 15:00-16:30

IV-12Massimiliano Germani

Population pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole.

Thursday 15:00-16:30

IV-13Leonid Gibiansky

Monoclonal Antibody-Drug Conjugates (ADC): TMDD Equations, Approximations, and Identifiability of Model Parameters

Thursday 15:00-16:30

IV-14Bill Gillespie

From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer’s Disease

Thursday 15:00-16:30

IV-15Pascal Girard

Simultaneous Ocular Adverse Event and Treatment Discontinuation Model of Pimasertib

Thursday 15:00-16:30

IV-16Sophie Glatt

A population pharmacokinetic analysis and pharmacokinetic/adverse events analysis of a sodium channel blocker in healthy subjects.

Thursday 15:00-16:30

IV-17

Title: Pharmacokinetic-Pharmacodynamic Modeling of the relationship between D2 receptor occupancy and Catalepsy in Rats: Predicting Extrapyramidal Side Effects in Humans

Thursday 15:00-16:30

IV-18

Population Pharmacokinetics of Two Volatile Markers Used for Assessment of Definitive Adherence

Thursday 15:00-16:30

IV-19Linus Görlitz

Physiological modeling of interindividual variability: PBPK-NLME vs. compartimental modeling

Thursday 15:00-16:30

IV-20Nathalie Gosselin

Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Paediatric Studies

Thursday 15:00-16:30

IV-21Verena Gotta

Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions

Thursday 15:00-16:30

IV-22Navin Goyal

Kinetic-Pharmaco Dynamic (K-PD) Modeling of a Novel Oral 5-Lipoxigenase Activating Protein (FLAP) Inhibitor for Asthma and its Comparison with a PK-PD Approach

Thursday 15:00-16:30

IV-23Iztok Grabnar

Enterohepatic Recirculation of Free and Conjugated Silybin Following Administration of a Chewing Gum with Milk Thistle Extract

Thursday 15:00-16:30

IV-24Joachim Grevel

Response type modelling and clinical trial simulation.

Thursday 15:00-16:30

IV-25Zheng Guan

Population PK/PD modeling to compare cannabinoid receptor antagonists in the THC challenge test

Thursday 15:00-16:30

IV-26Ivelina Gueorguieva

Development Of Integrated Pharmacokinetic/Pharmacodynamic (PK/PD) Model For The Novel TGF- β Inhibitor LY2157299 Monohydrate: Preclinical To Phase II

Thursday 15:00-16:30

IV-27Monia Guidi

Population Pharmacokinetics of Risperidone and 9-hydroxy-risperidone in psychiatric patients.

Thursday 15:00-16:30

IV-28Emma Hansson

PKPD Modeling of Predictors for Side Effects and Overall Survival in Patients with Gastro Intestinal Stromal Tumor Treated with Sunitinib

Thursday 15:00-16:30

IV-29Eva Hanze

Comparison of longitudinal data analysis to end of treatment data analysis when evaluating precision in dose-exposure-response in neuropathic pain studies.

Thursday 15:00-16:30

IV-30Lutz Harnisch

Determining the Pharmacokinetic (PK) Profile of Sildenafil in One Month to One Year Old Pediatric Pulmonary Arterial Hypertension (PAH) Patients Using Interpolation of Two Population Pharmacokinetic Models of Sildenafil in PPHN population (3 to 10 Days Old) and in Pediatric PAH population (1 to 17 Years Old)

Thursday 15:00-16:30

IV-31Tomi Hendrayana

Population pharmacokinetic (PK) model for fluorouracil (5-FU) accounting for irregularities in infusion rate

Thursday 15:00-16:30

IV-32Emilie Hénin

A latent-variable model for Sorafenib-induced Hand-Foot Syndrome (HFS) in non-selected patients to predict toxicity kinetics according to sorafenib administrations

Thursday 15:00-16:30

IV-33Stefanie Hennig

Pharmacokinetics of tobramycin do not differ in patients with and without cystic fibrosis

Thursday 15:00-16:30

IV-34

Pharmacokinetics Of High-Dose Methotrexate In Children With Cancer: A Mechanism Based Evalution Of Clearance Prediction

Thursday 15:00-16:30

IV-35Richard Höglund

A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated P.falciparum malaria

Thursday 15:00-16:30

IV-36Nick Holford

What is the between cycle variability in methotrexate clearance?

Thursday 15:00-16:30

IV-37Andrew Hooker

The Kaplan-Meier Mean Covariate plot (KMMC): a new diagnostic for covariates in time-to-event models.

Thursday 15:00-16:30

IV-38Daniel Hovdal

A mechanism-based population model for estimation of system parameters, vehicle effects and drug-induced body weight changes in diet induced obesity mice

Thursday 15:00-16:30

IV-39Xiao Hu

Comparison of Tolerance Models for Neopterin Elevation Following Interferon beta-1a or PEGylated Interferon beta-1a treatment in Rhesus Monkeys

Thursday 15:00-16:30

IV-40An Hyungmi

The Modified Bland-Altman Method to Measure Agreement with Repeated Measures Data using Random Effects Model

Thursday 15:00-16:30

IV-41Laura Iavarone

A population PK model combined with PK/PD model for analysis of headache in clinical trials

Thursday 15:00-16:30

IV-42Vijay Ivaturi

Individual Observation-Shrinkage Scaling of Residuals in a Generalized Least Square Type of Estimation in NONMEM

Thursday 15:00-16:30

IV-43Masoud Jamei

Model-Based Prediction of Domperidone and Ketoconazole Interaction and its Impact on QTc Prolongation

Thursday 15:00-16:30

IV-44Candice Jamois

Pharmacokinetic-Receptor Occupancy Modeling to support Phase 2 Dose Selection

Thursday 15:00-16:30

IV-45Alvaro Janda

Optimization of pharmacokinetics and pharmacodynamics profiles by optimal control methods. Application to a triptorelin-testosterone PD model.

Thursday 15:00-16:30

IV-46Juliette Janson

Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels in vivo.

Thursday 15:00-16:30

IV-47Roger Jelliffe

An Improved Population Model Prior for Nonparametric Sequential Interacting Multiple Model (IMM) Bayesian Analysis.

Thursday 15:00-16:30

IV-48

Population pharmacokinetic analysis of colistin in burn patients

Thursday 15:00-16:30

IV-49Amita Joshi

A physiologically-based pharmacokinetic (PBPK) approach to evaluate differences in pharmacokinetics between healthy subjects and cancer patients

Thursday 15:00-16:30

IV-50Matts Kågedal

Improved dose selection for PET occupancy studies

Thursday 15:00-16:30

IV-51

Modeling Sunitinib and Biomarker Response as potential Predictors of Time to Progression in Patients with Metastatic Colorectal Cancer

Thursday 15:00-16:30

IV-52

Therapeutic drug monitoring : modeling to assess risk and benefit for a novel drug used in combination

Thursday 15:00-16:30

IV-53Tatiana Karelina

Kinetic Model of Amyloid Beta Distribution and Allometric Scaling from Mouse to Monkey and Human

Thursday 15:00-16:30

IV-54Mats Karlsson

A full model approach based on the covariance matrix of parameters and covariates

Thursday 15:00-16:30

IV-55Nastya Kassir

A Modelling and Simulations Framework to Optimize Paediatric Studies and Facilitate Decision-Making

Thursday 15:00-16:30

IV-56Takayuki Katsube

Characterization of Stepwise Covariate Model Building Combined with Cross-Validation

Thursday 15:00-16:30

IV-57David Khan

In silico predictions of in vitro growth competition experiments between wild type and resistant mutants of E. coli MG1655 exposed to ciprofloxacin

Thursday 15:00-16:30

IV-58Frank Kloprogge

Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda

Thursday 15:00-16:30

IV-59

Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia

Thursday 15:00-16:30

IV-60Elke Krekels

Top-Down Modeling Meets Bottom-Up Modeling: The Physiological and Physicochemical Basis for the Ontogeny of UGT2B7-Mediated Drug Glucuronidation.

Thursday 15:00-16:30

IV-61Anders Kristoffersson

Robust optimal design of ciprofloxacin time-kill curve experiments with respect to autocorrelation

Thursday 15:00-16:30

IV-62Wojciech Krzyzanski

Methods of Solving Rapid Binding Target-Mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor

Thursday 15:00-16:30

IV-63Steve Kuan

Population Pharmacokinetic (PK) Modelling of Bortezomib After Bolus Intravenous Injection in Cancer Patients

Thursday 15:00-16:30

IV-64Brigitte Lacroix

A single population pharmacokinetic model for oral levetiracetam in various populations – dose investigation for Japanese children

Thursday 15:00-16:30

IV-65

Application of a new method for multivariate analysis of longitudinal ordinal data testing robenacoxib in canine osteoarthritis

Thursday 15:00-16:30

IV-66Cédric Laouenan

Modeling hepatitis C viral kinetics to compare antiviral potencies of two protease inhibitors: a simulation study under real conditions of use

Thursday 15:00-16:30

IV-67Anna Largajolli

Visual Predictive Check (VPC) in models with forcing functions

Thursday 15:00-16:30

IV-68

Use of an exposure-response model for lacosamide in adults with partial onset seizures to analyze preliminary data from a pediatric trial

Thursday 15:00-16:30

IV-69Marc Lavielle

On the use of stochastic differential mixed effects models for modeling inter occasion variability. Models and methods

Thursday 15:00-16:30